en 2024 Bryn Mawr Communications LLC Novartis Med Affairs Dry Eye Deep Dive no episodic Eyetube Novartis Med Affairs Dry Eye Deep Dive Novartis Med Affairs Dry Eye Deep Dive

]]> Bryn Mawr Communications (BMC) afu@bmctoday.com Carolina Betancurt, OD, MBA, Medical Director of Ophthalmology, Ophthalmics, Novartis Pharmaceuticals Corporation speaks with Douglas K. Devries, OD, Co-founder of Eye Care Associates of Nevada about the key takeaways of the TFOS DEWS II report and how to incorporate it into your practice. Wed, 06 Jan 2021 19:32:00 -0000 full Eyetube Carolina Betancurt, OD, MBA, Medical Director of Ophthalmology, Ophthalmics, Novartis Pharmaceuticals Corporation speaks with Douglas K. Devries, OD, Co-founder of Eye Care Associates of Nevada about the key takeaways of the TFOS DEWS II report and how to incorporate it into your practice. Carolina Betancurt, OD, MBA, Medical Director of Ophthalmology, Ophthalmics, Novartis Pharmaceuticals Corporation speaks with Douglas K. Devries, OD, Co-founder of Eye Care Associates of Nevada about the key takeaways of the TFOS DEWS II report and how to incorporate it into your practice.

]]> 501 no Megan Walton, OD, Medical Science Liaison, US Ophthalmics, Novartis Pharmaceuticals Corporation holds a discussion with Christopher Starr, MD, from Weill Cornell Medicine in New York City about visually and non-visually significant dry eye disease and managing a preoperative treatment course. Wed, 06 Jan 2021 19:31:00 -0000 full Eyetube Megan Walton, OD, Medical Science Liaison, US Ophthalmics, Novartis Pharmaceuticals Corporation holds a discussion with Christopher Starr, MD, from Weill Cornell Medicine in New York City about visually and non-visually significant dry eye disease and managing a preoperative treatment course. Megan Walton, OD, Medical Science Liaison, US Ophthalmics, Novartis Pharmaceuticals Corporation holds a discussion with Christopher Starr, MD, from Weill Cornell Medicine in New York City about visually and non-visually significant dry eye disease and managing a preoperative treatment course.

]]> 566 no Megan Walton, OD, Medical Science Liaison, US Ophthalmics, Novartis Pharmaceuticals Corporation holds a conversation with Laura Periman, MD, from the Periman Eye Institute in Seattle, Washington, and Christopher Starr, MD, from Weill Cornell Medicine in New York City about how to categorize and manage modifiable and non-modifiable risk factors of dry eye disease. Wed, 06 Jan 2021 19:29:00 -0000 full Eyetube Megan Walton, OD, Medical Science Liaison, US Ophthalmics, Novartis Pharmaceuticals Corporation holds a conversation with Laura Periman, MD, from the Periman Eye Institute in Seattle, Washington, and Christopher Starr, MD, from Weill Cornell Medicine in New York City about how to categorize and manage modifiable and non-modifiable risk factors of dry eye disease. Megan Walton, OD, Medical Science Liaison, US Ophthalmics, Novartis Pharmaceuticals Corporation holds a conversation with Laura Periman, MD, from the Periman Eye Institute in Seattle, Washington, and Christopher Starr, MD, from Weill Cornell Medicine in New York City about how to categorize and manage modifiable and non-modifiable risk factors of dry eye disease.

]]> 635 no Carolina Betancurt, OD, MBA, Medical Director of Ophthalmology, Ophthalmics, Novartis Pharmaceuticals Corporation speaks with Douglas K. Devries, OD, Co-founder of Eye Care Associates of Nevada, and Christopher Starr, MD, from Weill Cornell Medicine in New York City about optimizing the ocular surface, implementing dry eye screening into your practice, and utilizing the TFOS DEWS II treatment algorithm. Wed, 06 Jan 2021 19:29:00 -0000 full Eyetube Carolina Betancurt, OD, MBA, Medical Director of Ophthalmology, Ophthalmics, Novartis Pharmaceuticals Corporation speaks with Douglas K. Devries, OD, Co-founder of Eye Care Associates of Nevada, and Christopher Starr, MD, from Weill Cornell Medicine in New York City about optimizing the ocular surface, implementing dry eye screening into your practice, and utilizing the TFOS DEWS II treatment algorithm. Carolina Betancurt, OD, MBA, Medical Director of Ophthalmology, Ophthalmics, Novartis Pharmaceuticals Corporation speaks with Douglas K. Devries, OD, Co-founder of Eye Care Associates of Nevada, and Christopher Starr, MD, from Weill Cornell Medicine in New York City about optimizing the ocular surface, implementing dry eye screening into your practice, and utilizing the TFOS DEWS II treatment algorithm.

]]> 603 no and Leslie O'Dell, OD, from Medical Optometry America in York, Pennsylvania, discuss clinical signs and symptoms of dry eye disease, how dry eye disease affects patients’ corneal health, and options in testing and questionnaire use. Wed, 06 Jan 2021 19:27:00 -0000 full Eyetube and Leslie O'Dell, OD, from Medical Optometry America in York, Pennsylvania, discuss clinical signs and symptoms of dry eye disease, how dry eye disease affects patients’ corneal health, and options in testing and questionnaire use. and Leslie O'Dell, OD, from Medical Optometry America in York, Pennsylvania, discuss clinical signs and symptoms of dry eye disease, how dry eye disease affects patients’ corneal health, and options in testing and questionnaire use.

]]> 782 no